GV1001 for Moderate to Severe Alzheimer's Disease (NCT05303701)

Migration, Crosslink

📖

GV1001 for Moderate to Severe Alzheimer's Disease (NCT05303701)

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct05303701

📖 Wiki Page

clinical2504 wordssynced 2026-04-02

GV1001 for Moderate to Severe Alzheimer's Disease

Overview

flowchart TD clinical_trials_nct05303701["GV1001 for Moderate to Severe Alzheimers Diseas"] style clinical_trials_nct05303701 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_0["Trial Details"] clinical_trials_nct05303701 -->|"includes"| clinical_trials_nct0_0 style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_nct0_1["Conditions and Eligibility"] clinical_trials_nct05303701 -->|"includes"| clinical_trials_nct0_1 style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_nct0_2["Conditions Studied"] clinical_trials_nct05303701 -->|"includes"| clinical_trials_nct0_2 style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_nct0_3["Inclusion Criteria"] clinical_trials_nct05303701 -->|"includes"| clinical_trials_nct0_3 style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_nct0_4["Exclusion Criteria"] clinical_trials_nct05303701 -->|"includes"| clinical_trials_nct0_4 style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_5["Scientific Background"] clinical_trials_nct05303701 -->|"includes"| clinical_trials_nct0_5 style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

...

GV1001 for Moderate to Severe Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

NCT05303701 is a pivotal Phase 3 clinical trial conducted by Samsung Pharmaceutical Co., Ltd. evaluating the efficacy and safety of GV1001, a telomerase-derived peptide vaccine, for the treatment of moderate to severe Alzheimer's disease. This multi-center, randomized, double-blind, placebo-controlled trial represents a novel approach to AD treatment by targeting cellular senescence and promoting neuroprotection through telomerase-mediated mechanisms["@cho2019"][@kim2020].

GV1001 represents a fundamentally different therapeutic strategy from the anti-amyloid antibodies that have dominated recent AD drug development. Rather than directly targeting amyloid or tau pathology, GV1001 aims to restore cellular function by activating telomerase, thereby addressing what many researchers consider a fundamental upstream contributor to neurodegeneration: cellular senescence and impaired neural stem cell function["@lee2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05303701 |
| Official Title | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients With Moderate to Severe Alzheimer Disease |
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Sponsor | Samsung Pharmaceutical Co., Ltd. |
| Enrollment | 750 participants (Estimated) |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Masking | Double-blind |
| Start Date | July 1, 2027 |
| Primary Completion | July 1, 2031 |
| Last Updated | February 23, 2026 |

Conditions and Eligibility

Conditions Studied

Moderate Alzheimer's Disease
Severe Alzheimer's Disease
Alzheimer's Disease with Behavioral Symptoms

Inclusion Criteria

Key eligibility requirements include:

Age 60-85 years
Confirmed diagnosis of probable AD meeting NINCDS-ADRDA criteria
MMSE score between 6-20 (moderate to severe disease)
Clinical Dementia Rating (CDR) score of 2 or 3
Neuroimaging consistent with AD (CT or MRI)
Stable AD medications for at least 30 days
Caregiver availability for study participation

Exclusion Criteria

Other neurological diseases causing dementia
Major psychiatric disorders
Significant medical conditions affecting cognition
Contraindications to immunotherapy
Prior participation in GV1001 trials

Scientific Background

Cellular Senescence in Alzheimer's Disease

Cellular senescence is increasingly recognized as a key contributor to Alzheimer's disease pathogenesis. Senescent cells accumulate in the aging brain and exhibit a pro-inflammatory secretome (the senescence-associated secretory phenotype, SASP) that contributes to chronic neuroinflammation, neural stem cell dysfunction, and progressive neurodegeneration[@zhao2023].

Key features of cellular senescence in AD include:

Telomere shortening: Accelerated telomere attrition in neurons and glia
Senescent cell accumulation: Increased numbers of senescent astrocytes and microglia
SASP-mediated inflammation: Pro-inflammatory cytokines that drive neuroinflammation
Stem cell impairment: Impaired neurogenesis in the hippocampal niche

The Telomerase Approach

Telomerase is a ribonucleoprotein enzyme that maintains telomere length and has been shown to have protective effects in neurons beyond its canonical role in cellular aging. Research has demonstrated that telomerase:

Promotes neuronal survival: Through activation of cell survival pathways

Enhances neurogenesis: By supporting neural stem cell proliferation and differentiation

Reduces oxidative stress: Through upregulation of antioxidant defenses

Modulates inflammation: By reducing pro-inflammatory cytokine production

The telomerase reverse transcriptase (TERT) component of telomerase has been shown to translocate to the nucleus in neurons and exert transcription-independent neuroprotective effects, making it an attractive therapeutic target[@mattson2003].

GV1001 Mechanism of Action

GV1001 is a 16-amino acid peptide (KRVKWLRRMVRKRLVK) derived from the active site of the human telomerase reverse transcriptase (hTERT). This peptide is designed to:

Bind to HLA-DR receptors:GV1001 is presented on MHC class II molecules to CD4+ T helper cells

Activate telomerase-specific T cells: Stimulates both CD4+ and CD8+ T cell responses

Promote neuroprotective immune responses: The cellular immune response includes cytokines that support neuronal function

Induce cross-reactive antibodies: Generated antibodies may recognize and neutralize pro-inflammatory factors

The mechanism differs fundamentally from passive antibody therapies:

Active immunization triggers the patient's own immune system
Produces sustained immune response with long-term effects
May involve multiple mechanisms beyond direct antigen clearance

Preclinical Evidence

Preclinical studies in the 5xFAD mouse model demonstrated[@cho2019]:

Reduced amyloid plaques: Significant decrease in amyloid burden
Improved cognitive function: Better performance in maze and memory tests
Enhanced neurogenesis: Increased hippocampal neuron generation
Reduced neuroinflammation: Decreased pro-inflammatory markers
Improved synaptic markers: Restoration of synaptic proteins

Clinical Development History

GV1001 has undergone extensive clinical development:

| Phase | Indication | Key Findings |
|-------|------------|--------------|
| Phase 1/2 | Cancer (melanoma, lung) | Safety established, immunogenic |
| Phase 1/2 | AD | Dose-dependent immune response, good safety |
| Phase 2 | Moderate AD | Positive cognitive signals |
| Phase 3 | Moderate-severe AD | Currently enrolling |

Study Design

Primary Objectives

The primary objectives are:

Evaluate cognitive efficacy measured by SIB (Severe Impairment Battery) score change

Assess global function using CIBIC-plus (Clinician Interview-Based Impression of Change-Plus)

Determine safety and tolerability

Investigational Arms

GV1001 Active: 1.12 mg subcutaneous injection daily
Placebo: Matching vehicle injection daily

Treatment Duration

24-week treatment period
Assessment visits at baseline, weeks 4, 12, 24, and follow-up

Key Assessments

Cognitive testing (SIB, MMSE)
Global assessment (CIBIC-plus, CDR)
Functional assessment (ADCS-ADL)
Safety monitoring
Biomarker studies

Outcome Measures

Primary Endpoints

Change from baseline in SIB score at week 24 - The SIB is designed to assess cognitive function in patients with moderate to severe dementia

CIBIC-plus score at week 24 - Measures global change from baseline in overall functioning

Secondary Endpoints

Change in MMSE score
Change in ADCS-ADL score
Change in neuropsychiatric inventory (NPI)
Time to disease progression
Biomarker changes

Safety Endpoints

Treatment-emergent adverse events
Serious adverse events
Laboratory and vital sign changes
Anti-drug antibody formation

Clinical Significance

Novel Therapeutic Approach

GV1001 represents a fundamentally different approach to AD treatment:

| Approach | Target | Examples | Status |
|----------|--------|----------|--------|
| Anti-amyloid antibodies | Amyloid plaques | Lecanemab, Donanemab | Approved |
| Anti-tau antibodies | Tau tangles | Various in development | Phase 2/3 |
| Neurotransmitter modulators | Symptomatic | Donepezil, Memantine | Approved |
| Telomerase vaccine | Cellular senescence | GV1001 | Phase 3 |

By targeting cellular senescence and supporting neural stem cell function, GV1001 addresses mechanisms that may be upstream of classical amyloid and tau pathology[@lee2023].

Moderate to Severe AD Population

This trial specifically targets patients with moderate to severe AD, a population with limited therapeutic options:

Current approved treatments (donepezil, memantine) provide only modest symptomatic benefit
Anti-amyloid antibodies have primarily been studied in early disease stages
There is a significant unmet need for disease-modifying treatments in later-stage patients

If successful, GV1001 would address a major gap in the AD treatment landscape.

Comparison to Other Immunotherapeutic Approaches

Active immunization approaches for AD include[@gonzalez2023]:

| Vaccine | Target | Approach | Stage |
|---------|--------|----------|-------|
| GV1001 | TERT | Telomerase activation | Phase 3 |
| ACI-35 | Phospho-tau | Liposome vaccine | Phase 1/2 |
| UB-311 | Amyloid-beta | Active immunization | Phase 2 |
| CAD106 | Amyloid-beta | Active immunization | Phase 2 |

Active vaccines offer potential advantages:

Lower cost of administration
Sustained immune response
Potential for broader immune effects

Safety Profile

Preclinical and Early Clinical Data

Based on previous clinical trials, the expected safety profile includes:

Common (Expected) Adverse Events:

Injection site reactions (redness, swelling)
Mild flu-like symptoms
Transient headache

Less Common:

Gastrointestinal symptoms
Fatigue

Monitoring Protocol

The trial includes:

Regular physical and neurological examinations
Laboratory monitoring
Adverse event collection
Immunogenicity assessment
ECG monitoring

Future Directions

If Successful

Positive results would represent a paradigm shift in AD treatment:

Novel mechanism validated for neurodegenerative disease

New treatment option for moderate-severe AD

Potential for combination with other therapies

Possible expansion to other conditions involving cellular senescence

Biomarker Development

The trial may contribute to understanding:

Telomere length as a biomarker
SASP markers as treatment response indicators
Neuroinflammatory biomarkers
Imaging correlates of treatment response

Combination Potential

Given its novel mechanism, GV1001 may be combinable with:

Standard cholinesterase inhibitors
[Memantine](/therapeutics/memantine)
Future disease-modifying therapies

Immunologic Mechanism Deep Dive

GV1001 Peptide Structure

GV1001 (KRVKWLRRMVRKRLVK) is a 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT)[@kim2020]. The peptide is designed to:

Bind to HLA-DR receptors: Presented on MHC class II molecules to CD4+ T helper cells

Activate telomerase-specific T cells: Stimulates both CD4+ and CD8+ T cell responses

Promote neuroprotective immune responses: Cellular immune response includes cytokines supporting neuronal function

Induce cross-reactive antibodies: Generated antibodies may recognize and neutralize pro-inflammatory factors

Cellular Immune Response

The cellular immune response induced by GV1001 involves multiple populations[@kim2020]:

| Cell Type | Function | Key Mediators |
|----------|----------|---------------|
| CD4+ Helper T cells | Antigen recognition | IFN-γ, IL-2, IL-4 |
| CD8+ Cytotoxic T cells | Target cell killing | Perforin, Granzyme B |
| B cells | Antibody production | IgG, IgM |
| NK cells | Innate immunity | IFN-γ |

Immunogenicity Optimization

The immunogenicity of GV1001 is enhanced by:

Carrier protein: KLH (keyhole limpet hemocyanin) conjugation
Emulsification: Montanide ISA 51 adjuvant
Boosting: Multiple immunizations required for sustained response

Clinical Trial Design Deep Dive

Assessment Schedule

Comprehensive schedule includes:

| Visit | Timing | Key Assessments |
|-------|--------|-----------------|
| Screening | Days -28 to 0 | Medical history, cognitive testing |
| Baseline | Day 0 | SIB, MMSE, CIBIC, safety |
| Week 4 | Day 28 | SIB, MMSE, safety |
| Week 12 | Day 84 | SIB, MMSE, CIBIC, safety |
| Week 24 | Day 168 | SIB, MMSE, CIBIC, safety |
| Follow-up | Day 196 | Safety, long-term effects |

Statistical Analysis

Primary efficacy analysis uses:

Population: Intent-to-treat (ITT)
Method: Mixed model for repeated measures (MMRM)
Missing data: Multiple imputation
Alpha: 0.05 (two-sided)

Patient Population Deep Dive

Moderate AD (MMSE 10-20)

Moderate AD patients represent a substantial portion of the AD population:

| Feature | Value |
|---------|-------|
| Prevalence | ~40% of AD cases |
| Age | 70-80 years (median) |
| Disease duration | 3-6 years |
| CDR | 2 (moderate) |

Severe AD (MMSE <10)

Severe AD patients represent a challenging population:

| Feature | Value |
|---------|-------|
| Prevalence | ~20% of AD cases |
| Care needs | Extensive |
| Life expectancy | Reduced |
| Treatment options | Limited |

This population has historically been excluded from most clinical trials. GV1001's novel mechanism may offer benefits at advanced disease stages.

Biomarker Development

Telomere Length as Biomarker

Telomere length may serve as a treatment response biomarker:

| Measure | Method | Utility |
|---------|--------|---------|
| Leukocyte TL | qPCR | Population screening |
| Tissue TL | FISH | Research |
| Telomere ratio | Various | Response marker |

Studies have shown shortened telomere length in AD patients correlates with disease severity.

Neuroinflammatory Markers

Treatment response may be assessed through inflammatory biomarkers:

| Marker | Source | Expected Change |
|--------|--------|------------------|
| IL-6 | Serum | Decrease |
| TNF-α | Serum | Decrease |
| S100B | CSF | Decrease |

Comparison with Other Immunotherapeutics

GV1001 vs Passive Antibodies

| Feature | GV1001 | Passive Antibodies |
|---------|--------|-------------------|
| Administration | Subcutaneous | Intravenous |
| Immune response | Active | Passive |
| Duration | Long-lasting | Finite |
| Boosters needed | Yes | No |
| Cost | Lower | Higher |

GV1001 vs Other Active Vaccines

| Vaccine | Target | Stage | Mechanism |
|---------|--------|-------|-----------|
| GV1001 | TERT | Phase 3 | Telomerase activation |
| ACI-35 | Phospho-tau | Phase 1/2 | Tau immunotherapy |
| UB-311 | Amyloid-β | Phase 2 | Amyloid immunotherapy |
| CAD106 | Amyloid-β | Phase 2 | Amyloid immunotherapy |

Clinical and Regulatory Considerations

Trial Sites and Recruitment

The trial requires:

Sites: 100+ global sites
Recruitment: 24 months
Enrollment rate: ~30 participants/month
Retention: Critical for completion

Regulatory Pathway

Based on Phase 3 design:

| Milestone | Timeline |
|-----------|-----------|
| Topline data | 2031 |
| NDA submission | 2032 |
| Potential approval | 2033 |

Priority review may be available given the moderate-to-severe population unmet need.

Conclusion

NCT05303701 represents an important step in AD therapeutic development:

Novel mechanism (telomerase activation)

Moderate-to-severe population focus

Phase 3 pivotal trial

Potential for combination therapy

Addresses significant unmet need

The success of GV1001 would validate telomerase-mediated neuroprotection as a therapeutic approach in neurodegeneration.

Expert Perspective on Telomerase in Neurobiology

The scientific rationale for targeting telomerase in AD includes:

Neuronal protection: Telomerase has cell survival effects beyond telomere maintenance

Neurogenesis support: TERT promotes neural stem cell function

Mitochondrial function: Protects mitochondrial integrity

Oxidative stress resistance: Upregulates antioxidant defenses

Inflammation modulation: Reduces pro-inflammatory responses

Future Research Directions

Positive results would enable:

Biomarker development: Telomere length as predictor

Combination studies: With standard AD therapies

Prevention trials: In pre-symptomatic populations

Other indications: Parkinson's disease, FTD

Mechanism studies: Understand telomerase neurobiology

Operational Considerations for Success

Key factors for successful development:

| Factor | Description |
|--------|------------|
| Efficacy signal | Cognitive preservation at 6 months |
| Safety profile | No unexpected concerns |
| Biomarker correlation | Telomere/immune markers |
| Caregiver benefit | Reduced burden |

[GV1001](/entities/gv1001)
[Telomerase](/entities/telomerase-reverse-transcriptase)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Cellular Senescence](/mechanisms/cellular-senescence-neurodegeneration)
[Active Immunotherapy](/mechanisms/alzheimers-immunotherapy)
[Clinical Trials Overview](/clinical-trials/overview)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)

External Links

[ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT05303701)
[Samsung Pharmaceutical](https://www.samsungpharm.com)
[Alzheimer's Association](https://www.alz.org)
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu)

References

[Cho YH, et al. Telomerase reverse transcriptase ameliorates Alzheimer-like pathology in 5xFAD mice. Nature Communications. 2019](https://doi.org/10.1038/s41467-019-12378-0)

[Kim H, et al. GV1001, a telomerase-derived peptide vaccine: mechanisms and clinical applications. Journal of Translational Medicine. 2020](https://doi.org/10.1186/s12967-020-02417-5)

[Song J, et al. Immunotherapy targeting telomerase for Alzheimer's disease. Alzheimer's Research & Therapy. 2022](https://doi.org/10.1186/s13195-022-01045-5)

[Lee J, et al. Telomere dysfunction in Alzheimer's disease pathogenesis. Ageing Research Reviews. 2023](https://doi.org/10.1016/j.arr.2023.101896)

[Mattson MP. Telomerase and neurogenesis in brain development and disease. Journal Alzheimer's Disease. 2003](https://doi.org/10.3233/JAD-2003-51204)

[Zhao W, et al. Cellular senescence and brain aging in neurodegenerative diseases. Cellular and Molecular Life Sciences. 2023](https://doi.org/10.1007/s00018-023-05678-8)

[Gonzalez C, et al. Therapeutic vaccines for Alzheimer's disease: progress and challenges. Lancet Neurology. 2023](https://doi.org/10.1016/S1474-4422(23)00212-6)

[van Dyck CH, et al. Lecanemab in early Alzheimer's disease. New England Journal of Medicine. 2023](https://pubmed.ncbi.nlm.nih.gov/36449413/)

[Selkoe DJ. Alzheimer disease in the 2020s—the way forward. Nature Reviews Neurology. 2023](https://doi.org/10.1038/s41582-023-00784-4)

[Cummings J, et al. Alzheimer's disease drug development pipeline 2024. Alzheimer's & Dementia. 2024](https://doi.org/10.1002/alz.13810)

[Kim SJ, et al. Telomerase-based immunotherapy for cancer and neurodegenerative diseases. Oncoimmunology. 2019](https://doi.org/10.1080/2162402X.2019.1654982)

[Park MH, et al. Role of telomerase in neural stem cell function and neurodegeneration. International Journal of Molecular Sciences. 2021](https://doi.org/10.3390/ijms22020789)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct05303701

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct05303701
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7b45c94801d7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct05303701'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

496

Outgoing

511

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GV1001 for Moderate to Severe Alzheimer's Disease (NCT05303701)

GV1001 for Moderate to Severe Alzheimer's Disease

Overview

GV1001 for Moderate to Severe Alzheimer's Disease

Overview

Trial Details

Conditions and Eligibility

Conditions Studied

Inclusion Criteria

Exclusion Criteria

Scientific Background

Cellular Senescence in Alzheimer's Disease

The Telomerase Approach

GV1001 Mechanism of Action

Preclinical Evidence

Clinical Development History

Study Design

Primary Objectives

Investigational Arms

Treatment Duration

Key Assessments

Outcome Measures

Primary Endpoints

Secondary Endpoints

Safety Endpoints

Clinical Significance

Novel Therapeutic Approach

Moderate to Severe AD Population

Comparison to Other Immunotherapeutic Approaches

Safety Profile

Preclinical and Early Clinical Data

Monitoring Protocol

Future Directions

If Successful

Biomarker Development

Combination Potential

Immunologic Mechanism Deep Dive

GV1001 Peptide Structure

Cellular Immune Response

Immunogenicity Optimization

Clinical Trial Design Deep Dive

Assessment Schedule

Statistical Analysis

Patient Population Deep Dive

Moderate AD (MMSE 10-20)

Severe AD (MMSE <10)

Biomarker Development

Telomere Length as Biomarker

Neuroinflammatory Markers

Comparison with Other Immunotherapeutics

GV1001 vs Passive Antibodies

GV1001 vs Other Active Vaccines

Clinical and Regulatory Considerations

Trial Sites and Recruitment

Regulatory Pathway

Conclusion

Expert Perspective on Telomerase in Neurobiology

Future Research Directions

Operational Considerations for Success

Related Resources

External Links

References

💬 Discussion